Research letterIncidence and risk of developing photosensitivity with targeted anticancer therapies
References (5)
- et al.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Lancet Oncol
(2012) - et al.
Improved overall survival in melanoma with combined dabrafenib and trametinib
New Engl J Med
(2015)
Cited by (5)
Photosensitive rash induced by nivolumab
2022, Anais Brasileiros de DermatologiaCitation Excerpt :Several cases of subacute cutaneous lupus induced by nivolumab have also been reported3,4. Ciccolini et al.5 has reported recently a systematic review regarding the risk of photosensitivity with immunotherapy against melanoma. Vemurafenib and vandetanib have been communicated as the main therapies with a higher risk of photosensitivity.
Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
2022, Anais Brasileiros de DermatologiaCitation Excerpt :It can be caused by both classical chemotherapy and target therapy. In the first group, those with the highest association are dacarbazine, 5-fluorouracil, tegafur, and capecitabine; in the second, vandetanib, vemurafenib, and nivolumab.6,19,20 In the present study, representatives of both classes were found to be responsible for this adverse effect (with two cases secondary to classic chemotherapy, due to the use of capecitabine and paclitaxel and one case due to the use of target therapy with vandetanib).
Photosensitivity From Avapritinib: Pharamacovigilance Analysis
2022, JMIR DermatologyAnticancer treatments and photosensitivity
2022, Journal of the European Academy of Dermatology and Venereology
Funding sources: Supported in part through the National Institutes of Health, National Cancer Institute, Cancer Center Support Grant P30 CA008748.
Conflicts of interest: Dr Lacouture is a consultant and speaker for Legacy Healthcare Services, Adgero Bio Pharmaceuticals, Amryt Pharmaceuticals, Celldex Therapeutics, Debiopharm, Galderma Research and Development, Johnson and Johnson, Novocure Inc, Lindi, Merck Sharp and Dohme Corporation, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim Pharma Gmbh & Co. KG, Allergan Inc, Amgen Inc, E.R. Squibb & Sons LLC, EMD Serono Inc, Astrazeneca Pharmaceuticals LP, Genentech Inc, Leo Pharma Inc, Seattle Genetics, Bayer, Manner SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd, Novartis, and Our Brain Bank. Dr Lacouture also receives research funding from Berg, Bristol-Myers Squibb, Lutris, Paxman, Novocure, US Biotest, and Veloce. Dr Lacouture received royalties as a consultant for Takeda Milledium. Ms Ciccolini, Mr Kim, Dr Chaudhari, Dr Lucas, Dr Benhuri, Dr Duran, and Dr Wu have no conflicts of interest to disclose.